Contact
Professor, Faculty of Medicine & Dentistry - Oncology Dept
- msawyer@ualberta.ca
- Phone
- (780) 432-8248
- Address
-
Cross Cancer Institute
11560 University AvenueEdmonton ABT6G 1Z2
Overview
Area of Study / Keywords
About
Academic InterestsTranslational cancer research, Phase I studies/Drug Development, Clinical Pharmacology of Anticancer Drugs, and Pharmacogenetics
Clinical Practice
Gastrointestinal Malignancies, Neuroendocrine Tumors, Phase I Studies
Research
Clinical Trials Research:
My interest in clinical trials is focused on gastrointestinal malignancies and neuroendocrine tutors. Along with Quincy Chu, we are establishing a phase I program at the Cross Cancer Institute.
Fundamental/Translational Research:
My focus is on of anticancer drugs. My research interests and collaborations are broad but are unified by the common thread of trying to understand causes of interpatient variability in terms of toxicity and efficacy. My major interest is understanding mechanisms of nephrotoxicity of chemotherapy especially antifolates and nucleoside analogues. My major collaborator in this research is Carol E. Cass, an international expert in nucleoside transport and therapeutics. Pharmacogenetics is another major interest that I developed during my training with M. Ratain. I am interested in the roles that polymorphisms play in the interpatient variation in drug elimination. I am also interested in the role that nutrition plays in the toxicity and efficacy of chemotherapy and have developed extensive collaborations with Drs. Vickie Baracos and Catherine Field. The research has been supported by the Alberta Cancer Board, Alberta Cancer Foundation, The Canadian Breast Cancer Foundation, The Canadian Breast Cancer Research Alliance and the Canadian Institutes of Health Research. I have received funding from Hoffman La Roche, Pfizer and .
Featured Publications
Annual Meeting of American Society of Clinical Oncology. 2022 June; 10.1200/JCO.2022.40.16_suppl.3573
Cancer Res (2022) 82 (12_Supplement): CT006. 2022 June; 10.1158/1538-7445.AM2022-CT006
Annual Meeting of the American Society of Clinical Oncology. 2022 June; 10.1200/JCO.2022.40.16_suppl.3614
Abdel-Rahman O., Pham T.M., Pokhrel A., Ruether D., Sawyer M.B.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. 2022 May; 45 (5):208-214 10.1097/COC.0000000000000906
Youn S., Eurich D.T., McCall M., Walker J., Smylie M., Sawyer M.B.
CLINICAL NUTRITION. 2022 May; 41 (5):1066-1072 10.1016/j.clnu.2022.03.001
Giani J., Chambers C.R., Sawyer M.B.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2022 March; 28 (2):457-461 10.1177/10781552211038031
Youn S., Jogiat U., Baracos V.E., McCall M., Eurich D.T., Sawyer M.B.
Clinical Nutrition ESPEN. 2021 October; 45 10.1016/j.clnesp.2021.06.029
Joy A.A., Vos L.J., Pituskin E., Cook S.F., Bies R.R., Vlahadamis A., King K., Basi S.K., Meza-Junco J., Mackey J.R., Stanislaus A., Damaraju V.L., Damaraju S., Sawyer M.B.
Clinical Breast Cancer. 2021 October; 21 (5):e584-e593 10.1016/j.clbc.2021.03.001
Youn S., Chen A., Ha V., Chambers C., Eurich D.T., McCall M., Sawyer M.B.
CLINICAL NUTRITION. 2021 August; 40 (8):4888-4892 10.1016/j.clnu.2021.06.026
Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)
Journal of Clinical Oncology, 2021. 39(15_suppl): p. 4090-4090.. 2021 June;
Damaraju V.L., Aminpour M., Kuzma M., Winter P., Preto J., Tuszynski J., McEwan A.B.J., Sawyer M.B.
CTS-Clinical and Translational Science. 2021 May; 14 (3):847-858 10.1111/cts.12943
Youn S., Reif R., Chu M.P., Smylie M., Walker J., Eurich D.T., Ghosh S., Sawyer M.B.
EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2021 April; 42 10.1016/j.clnesp.2021.01.009
Sarcopenia predicts dose-limiting toxicity in pancreatic cancer treated with nab-paclitaxel and gemcitabine
American Association of Cancer Researchers Annual Meeting 2021. 2021 April;
Giani J., Sawyer M.B., Chambers C.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2021 March; 27 (2):447-479 10.1177/1078155220934163
Nath E., Sawyer M.B., Choy J.
Case Reports in Oncology. 2021 January; 13 (3):1454-1462 10.1159/000511414
Ford K.L., Sawyer M.B., Trottier C.F., Ghosh S., Deutz N.E.P., Siervo M., Porter Starr K.N., Bales C.W., Disi I.R., Prado C.M.
Clinical Nutrition ESPEN. 2021 January; 41 10.1016/j.clnesp.2020.11.016
Sarcopenia predicts dose-limiting toxicity in pancreatic cancer treated with nab-paclitaxel and gemcitabine
13th international SCWD digital conference on cachexia, sarcopenia and muscle wasting. 2020 December;
van der Meij B.S., Teleni L., Stanislaus A.E., Murphy R.A., Robinson L., Damaraju V.L., Chu Q., Sawyer M.B., Mazurak V.
Clinical Nutrition ESPEN. 2020 November; 40 10.1016/j.clnesp.2020.09.009